(Q51740150)

English

Effectiveness of first-line treatment with recombinant interleukin-1 receptor antagonist in steroid-naive patients with new-onset systemic juvenile idiopathic arthritis: results of a prospective cohort study.

scientific article published in April 2014

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

11 April 2018

http://europepmc.org/abstract/MED/24757154

Effectiveness of first-line treatment with recombinant interleukin-1 receptor antagonist in steroid-naive patients with new-onset systemic juvenile idiopathic arthritis: results of a prospective cohort study. (English)

1 reference

Europe PubMed Central

PubMed publication ID

11 April 2018

http://europepmc.org/abstract/MED/24757154

0 references

juvenile rheumatoid arthritis

1 reference

based on heuristic

inferred from title

2

1 reference

Europe PubMed Central

PubMed publication ID

11 April 2018

http://europepmc.org/abstract/MED/24757154

Nico M Wulffraat

7

object named as

Nico M Wulffraat

1 reference

Europe PubMed Central

PubMed publication ID

11 April 2018

http://europepmc.org/abstract/MED/24757154

author name string

Sebastiaan J Vastert

1

1 reference

Europe PubMed Central

PubMed publication ID

11 April 2018

http://europepmc.org/abstract/MED/24757154

Bo Jan Noordman

3

1 reference

Europe PubMed Central

PubMed publication ID

11 April 2018

http://europepmc.org/abstract/MED/24757154

Dirk Holzinger

4

1 reference

Europe PubMed Central

PubMed publication ID

11 April 2018

http://europepmc.org/abstract/MED/24757154

Wietse Kuis

5

1 reference

Europe PubMed Central

PubMed publication ID

11 April 2018

http://europepmc.org/abstract/MED/24757154

Berent J Prakken

6

1 reference

Europe PubMed Central

PubMed publication ID

11 April 2018

http://europepmc.org/abstract/MED/24757154

publication date

1 April 2014

1 reference

Europe PubMed Central

PubMed publication ID

11 April 2018

http://europepmc.org/abstract/MED/24757154

Arthritis & Rheumatology

1 reference

Europe PubMed Central

PubMed publication ID

11 April 2018

http://europepmc.org/abstract/MED/24757154

66

1 reference

Europe PubMed Central

PubMed publication ID

11 April 2018

http://europepmc.org/abstract/MED/24757154

4

1 reference

Europe PubMed Central

PubMed publication ID

11 April 2018

http://europepmc.org/abstract/MED/24757154

1034-1043

1 reference

Europe PubMed Central

PubMed publication ID

11 April 2018

http://europepmc.org/abstract/MED/24757154

Systemic juvenile idiopathic arthritis: diagnosis, management, and outcome

1 reference

https://api.crossref.org/works/10.1002%2FART.38296

21 January 2018

New insights in systemic juvenile idiopathic arthritis--from pathophysiology to treatment

1 reference

https://api.crossref.org/works/10.1002%2FART.38296

21 January 2018

Does systemic-onset juvenile idiopathic arthritis belong under juvenile idiopathic arthritis?

1 reference

https://api.crossref.org/works/10.1002%2FART.38296

21 January 2018

Systemic JIA: new developments in the understanding of the pathophysiology and therapy

1 reference

https://api.crossref.org/works/10.1002%2FART.38296

21 January 2018

Natural killer cell dysfunction: A common pathway in systemic-onset juvenile rheumatoid arthritis, macrophage activation syndrome, and hemophagocytic lymphohistiocytosis?

1 reference

https://api.crossref.org/works/10.1002%2FART.38296

21 January 2018

Role of interleukin-1 (IL-1) in the pathogenesis of systemic onset juvenile idiopathic arthritis and clinical response to IL-1 blockade

1 reference

https://api.crossref.org/works/10.1002%2FART.38296

21 January 2018

Randomized trial of tocilizumab in systemic juvenile idiopathic arthritis

1 reference

https://api.crossref.org/works/10.1002%2FART.38296

21 January 2018

The pattern of response to anti-interleukin-1 treatment distinguishes two subsets of patients with systemic-onset juvenile idiopathic arthritis

1 reference

https://api.crossref.org/works/10.1002%2FART.38296

21 January 2018

Systemic juvenile idiopathic arthritis

1 reference

https://api.crossref.org/works/10.1002%2FART.38296

21 January 2018

Pathogenesis of systemic juvenile idiopathic arthritis: some answers, more questions

1 reference

https://api.crossref.org/works/10.1002%2FART.38296

21 January 2018

Two randomized trials of canakinumab in systemic juvenile idiopathic arthritis

1 reference

https://api.crossref.org/works/10.1002%2FART.38296

21 January 2018

Correlation of serum interleukin-6 levels with joint involvement and thrombocytosis in systemic juvenile rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1002%2FART.38296

21 January 2018

Serum soluble interleukin 6 (IL-6) receptor and IL-6/soluble IL-6 receptor complex in systemic juvenile rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1002%2FART.38296

21 January 2018

Blood and synovial fluid cytokine signatures in patients with juvenile idiopathic arthritis: a cross-sectional study.

1 reference

https://api.crossref.org/works/10.1002%2FART.38296

21 January 2018

The myeloid-related proteins 8 and 14 complex, a novel ligand of toll-like receptor 4, and interleukin-1beta form a positive feedback mechanism in systemic-onset juvenile idiopathic arthritis

1 reference

https://api.crossref.org/works/10.1002%2FART.38296

21 January 2018

Natural killer cell dysfunction is a distinguishing feature of systemic onset juvenile rheumatoid arthritis and macrophage activation syndrome

1 reference

https://api.crossref.org/works/10.1002%2FART.38296

21 January 2018

Natural killer cell dysfunction in patients with systemic-onset juvenile rheumatoid arthritis and macrophage activation syndrome

1 reference

https://api.crossref.org/works/10.1002%2FART.38296

21 January 2018

Defective phosphorylation of interleukin-18 receptor beta causes impaired natural killer cell function in systemic-onset juvenile idiopathic arthritis.

1 reference

https://api.crossref.org/works/10.1002%2FART.38296

21 January 2018

Macrophage activation syndrome.

1 reference

https://api.crossref.org/works/10.1002%2FART.38296

21 January 2018

Mutations in the perforin gene can be linked to macrophage activation syndrome in patients with systemic onset juvenile idiopathic arthritis.

1 reference

https://api.crossref.org/works/10.1002%2FART.38296

21 January 2018

Macrophage activation syndrome in patients with systemic juvenile idiopathic arthritis is associated with MUNC13-4 polymorphisms

1 reference

https://api.crossref.org/works/10.1002%2FART.38296

21 January 2018

The German etanercept registry for treatment of juvenile idiopathic arthritis

1 reference

https://api.crossref.org/works/10.1002%2FART.38296

21 January 2018

Long-term outcome of patients with JIA treated with etanercept, results of the biologic register JuMBO.

1 reference

https://api.crossref.org/works/10.1002%2FART.38296

21 January 2018

Factors associated with treatment response to etanercept in juvenile idiopathic arthritis

1 reference

https://api.crossref.org/works/10.1002%2FART.38296

21 January 2018

Effectiveness and safety of a second and third biological agent after failing etanercept in juvenile idiopathic arthritis: results from the Dutch National ABC Register

1 reference

https://api.crossref.org/works/10.1002%2FART.38296

21 January 2018

Interleukin-1 receptor antagonist (anakinra) treatment in patients with systemic-onset juvenile idiopathic arthritis or adult onset Still disease: preliminary experience in France

1 reference

https://api.crossref.org/works/10.1002%2FART.38296

21 January 2018

A multicentre, randomised, double-blind, placebo-controlled trial with the interleukin-1 receptor antagonist anakinra in patients with systemic-onset juvenile idiopathic arthritis (ANAJIS trial)

1 reference

https://api.crossref.org/works/10.1002%2FART.38296

21 January 2018

The efficacy and safety of interleukin-1-receptor antagonist anakinra in the treatment of systemic juvenile idiopathic arthritis

1 reference

https://api.crossref.org/works/10.1002%2FART.38296

21 January 2018

Anakinra as first-line disease-modifying therapy in systemic juvenile idiopathic arthritis: report of forty-six patients from an international multicenter series

1 reference

https://api.crossref.org/works/10.1002%2FART.38296

21 January 2018

2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: initiation and safety monitoring of therapeutic agents for the treatment of arthritis and systemic features

1 reference

https://api.crossref.org/works/10.1002%2FART.38296

21 January 2018

Cytokine multiplex immunoassay: methodology and (clinical) applications

1 reference

https://api.crossref.org/works/10.1002%2FART.38296

21 January 2018

Proinflammatory S100 proteins in arthritis and autoimmune disease

1 reference

https://api.crossref.org/works/10.1002%2FART.38296

21 January 2018

Pulmonary hypertension and other potentially fatal pulmonary complications in systemic juvenile idiopathic arthritis

1 reference

https://api.crossref.org/works/10.1002%2FART.38296

21 January 2018

A phase II, multicenter, open-label study evaluating dosing and preliminary safety and efficacy of canakinumab in systemic juvenile idiopathic arthritis with active systemic features.

1 reference

https://api.crossref.org/works/10.1002%2FART.38296

21 January 2018

The Toll-like receptor 4 agonist MRP8/14 protein complex is a sensitive indicator for disease activity and predicts relapses in systemic-onset juvenile idiopathic arthritis.

1 reference

https://api.crossref.org/works/10.1002%2FART.38296

21 January 2018

Distinct cytokine profiles of systemic-onset juvenile idiopathic arthritis-associated macrophage activation syndrome with particular emphasis on the role of interleukin-18 in its pathogenesis

1 reference

https://api.crossref.org/works/10.1002%2FART.38296

21 January 2018

Early predictors of poor functional outcome in systemic-onset juvenile rheumatoid arthritis: a multicenter cohort study

1 reference

https://api.crossref.org/works/10.1002%2FART.38296

21 January 2018

Identifiers

10.1002/ART.38296

1 reference

Europe PubMed Central

PubMed publication ID

11 April 2018

http://europepmc.org/abstract/MED/24757154

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

11 April 2018

http://europepmc.org/abstract/MED/24757154

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q51740150&oldid=1620236409"